Olympus (7733)--Why the Offering Is a Long-Term Buying Opportunity
Olympus announced a second-party share offering after market close on Friday, November 24th. This $406m offering (based on Friday's closing price)...
188 Views
U.S. Equity Strategy: Reiterating Biotechs, Gold Miners; Downgrading Financials to Market Weight
Key themes: Downgrading Financials. Given the Sector’s relative deterioration, we are downgrading Financials to market weight. Pockets of strength...
482 Views
Olympus--Dead Money for Momentum Investors; Dip-Buying Time for Long-Term Investors
Olympus generates 98% of its profits from endoscopes sales and has a 70% global share of gastro enteral endoscope systems. Their current line-up is...
258 Views
Trump Health Effect: What Is Next for the Consumer Health Industry Under Trump's Leadership?
While the US consumer health industry will remain a strong centre for investment, development and technology innovation in 2017 and is expected to...
3.2k Views
Relapsed/Refractory Acute Myeloid Leukemia (R/R AML)
AML represents one of the largest hematologic cancer populations with one of the worst survival rates. Global prevalence is expected to increase at...
515 Views